0.05% Archives - CDR – Chain Drug Review

Akorn gets FDA nod for betamethasone dipropionate lotion USP

October 15, 2019 by Chain Drug Review 0.05%, Akorn, betamethasone dipropionate lotion (Augmented) Pharmacy, Supplier News

LAKE FOREST, Ill. — Akorn, a leading specialty pharmaceutical company, Monday announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for betamethasone dipropionate lotion USP (Augmented), 0.05%. The product is manufactured at Akorn’s Amityville, N.Y. manufacturing facility.According to IQVIA, U.S. sales of betamethasone dipropionate

Glenmark receives ANDA approval for clobetasol propionate foam

September 10, 2019 by Chain Drug Review 0.05%, 0.05% (Emulsion Formulation), clobetasol propionate foam, generic version of Olux 1-E Foam, Glenmark Pharmaceuticals, of Mylan Pharmacy, Supplier News

MUMBAI — Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for clobetasol propionate foam, 0.05% (Emulsion Formulation), a generic version of Olux 1-E Foam, 0.05%, from Mylan. According to IQVIATM sales data for the 12 month period ending July 2019, the Olux-E Foam, 0.05% market achieved